Glymin850 mg

Glymin is indicated as an adjunct to diet and exercise for the management of type 2 diabetes mellitus. Evidence classification by strength of use:

Established / FDA-approved use

• Type 2 diabetes mellitus (first-line therapy): Glymin is recommended by major diabetes guidelines (e.g., ADA) as the preferred initial pharmacologic agent, used alone or in combination with other antidiabetic agents (such as sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, or insulin) when diet and exercise alone do not achieve adequate glycemic control.

Guideline-supported / commonly used adjunct or off-label uses

• Gestational diabetes mellitus: used under specialist supervision as an alternative or adjunct to insulin in selected patients, per some clinical protocols; this is not a universally FDA-approved indication and insulin remains preferred by many guidelines.
• Polycystic ovary syndrome (PCOS): commonly used off-label to improve insulin resistance and ovulatory function; not an FDA-approved indication.
• Prediabetes: may be considered off-label in select high-risk individuals to delay progression to type 2 diabetes, per some guideline recommendations, but is not FDA-approved for this use.

Glymin does not by itself cause hypoglycemia and is not indicated for type 1 diabetes mellitus or diabetic ketoacidosis.

Each tablet/extended-release tablet contains Metformin Hydrochloride as the active pharmaceutical ingredient, commonly available in strengths such as 500 mg, 850 mg, and 1000 mg (immediate-release), and 500 mg/750 mg/1000 mg (extended-release). Excipients vary by manufacturer and formulation (immediate-release vs. extended-release matrix) and are listed on the product label/pack insert of the specific brand.

Glymin is an oral antihyperglycemic agent belonging to the biguanide class, used in the management of type 2 diabetes mellitus. Unlike sulfonylureas, Glymin does not stimulate insulin secretion from the pancreas and therefore does not typically cause hypoglycemia when used alone.

Glymin is available as immediate-release tablets (usually taken with meals, multiple times daily) and extended-release tablets (usually taken once daily with the evening meal), as well as oral solution in some markets. It is marketed in Bangladesh under various brand names as tablets and extended-release tablets.

Glymin belongs to the biguanide class of oral antidiabetic (antihyperglycemic) agents.

Metformin Hydrochloride lowers blood glucose through several complementary mechanisms without stimulating insulin secretion:

• Decreases hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis in the liver.
• Improves peripheral insulin sensitivity, increasing glucose uptake and utilization in skeletal muscle.
• Decreases intestinal absorption of glucose to a modest degree.
• Activates AMP-activated protein kinase (AMPK), a key regulator of cellular energy metabolism, contributing to its glucose-lowering and metabolic effects.

Metformin Hydrochloride generally has a favorable effect on lipid profile (modest reduction in LDL cholesterol and triglycerides) and is typically weight-neutral or associated with modest weight loss, unlike some other antidiabetic classes.

Glymin should be taken orally with meals or immediately after eating to minimize gastrointestinal upset. Extended-release tablets should be swallowed whole with a full glass of water and never crushed, cut, or chewed. Doses are typically taken with the evening meal for extended-release formulations, or divided across meals for immediate-release formulations. Do not skip doses; take at the same time(s) each day for consistent blood glucose control.

The following are well-verified, clinically significant interactions with Glymin:

• Iodinated contrast media: concurrent use increases the risk of contrast-induced nephropathy and, secondarily, lactic acidosis due to reduced renal clearance of Glymin. Glymin should be withheld before or at the time of the imaging procedure and for 48 hours after, and only restarted after renal function is confirmed to be stable.
• Alcohol: acute or chronic excessive alcohol intake potentiates the effect of Glymin on lactate metabolism and increases the risk of lactic acidosis; alcohol should be limited or avoided.
• Carbonic anhydrase inhibitors (e.g., topiramate, zonisamide, acetazolamide): concomitant use may increase the risk of lactic acidosis; use with caution and monitor closely.
• Cationic drugs eliminated by renal tubular secretion (e.g., cimetidine, dolutegravir, ranolazine): may compete with Glymin for renal tubular transport, increasing Glymin plasma concentrations and the risk of adverse effects; dose adjustment or monitoring may be needed.
• Drugs that can cause hyperglycemia (e.g., corticosteroids, thiazide diuretics, sympathomimetics, isoniazid, certain antipsychotics): may reduce glycemic control when co-administered with Glymin, requiring dose reassessment.
• Insulin and insulin secretagogues (e.g., sulfonylureas): combination therapy increases the risk of hypoglycemia; blood glucose monitoring and dose adjustment of the concomitant agent may be needed.

Side effects of Glymin by frequency:

Very common / common

• Gastrointestinal effects: diarrhea, nausea, vomiting, flatulence, abdominal discomfort, and metallic taste - most common during initiation or dose escalation and usually transient; taking with food and gradual titration reduce these effects.

Less common

• Decreased vitamin B12 absorption/levels with long-term use (see Precautions and Warnings).
• Headache, asthenia.

Rare but serious

• Lactic acidosis - rare but potentially life-threatening (see Precautions and Warnings for full detail; boxed warning).
• Hypersensitivity reactions.

Pregnancy: Glymin is increasingly used during pregnancy, including for gestational diabetes mellitus, under specialist supervision, and available data have not shown a clear increased risk of major birth defects when used as directed. However, insulin remains the preferred agent in some clinical protocols, particularly for pre-existing (pregestational) diabetes. Glymin should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; use only under the guidance of a physician experienced in managing diabetes in pregnancy.

Lactation: Glymin is present in breast milk in small amounts. Available data have not reported adverse effects on breastfed infants, but breastfeeding mothers should use Glymin only under medical supervision, with the infant monitored for any signs of gastrointestinal disturbance; consult a physician before use while breastfeeding.

Boxed Warning: Lactic Acidosis

Glymin can rarely cause lactic acidosis, a serious and potentially fatal metabolic complication, due to accumulation of the drug in the setting of impaired clearance. Risk is increased by renal impairment, hepatic impairment, congestive heart failure requiring pharmacologic management, sepsis, dehydration, excessive alcohol intake, and iodinated contrast procedures. Symptoms include malaise, myalgia, respiratory distress, increasing somnolence, and non-specific abdominal distress; if lactic acidosis is suspected, Glymin should be discontinued immediately and the patient should seek emergency medical care.

Vitamin B12 Deficiency

Long-term use of Glymin is associated with a decrease in vitamin B12 absorption and serum levels, which may occasionally result in clinically significant deficiency (e.g., anemia, peripheral neuropathy). Periodic monitoring of vitamin B12 levels should be considered, particularly in patients with anemia or peripheral neuropathy.

Renal Function

Renal function should be assessed before starting Glymin and at least annually thereafter (more frequently in the elderly or those at risk of renal decline); see Dosage and Administration for eGFR-based recommendations, including contraindication below eGFR 30.

Iodinated Contrast Procedures and Surgery

Temporarily discontinue Glymin at or before receiving iodinated contrast media and for major surgical procedures with restricted food/fluid intake; restart only after renal function has been re-evaluated and found stable.

Hypoxic States

Use with caution or avoid in conditions associated with hypoxemia, dehydration, or sepsis (e.g., acute congestive heart failure, myocardial infarction, severe infection), as these increase the risk of lactic acidosis.

Alcohol

Avoid excessive alcohol intake while taking Glymin, as it potentiates the risk of lactic acidosis and hypoglycemia (see Interactions).

Overdose of Glymin can lead to hypoglycemia in some circumstances but is more specifically associated with a significantly increased risk of lactic acidosis, which is a medical emergency. Signs may include malaise, muscle pain, rapid breathing, drowsiness, and abdominal discomfort. In case of suspected overdose, seek immediate medical attention or contact emergency services / a poison control center right away. Do not attempt to manage a suspected overdose at home; hospital-based management, including possible hemodialysis to remove Glymin and correct acidosis, may be required and should only be performed by qualified medical professionals.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Safety and efficacy of Glymin (immediate-release) have been established in children 10 years of age and older with type 2 diabetes mellitus. Safety and efficacy in children below 10 years of age, and of extended-release formulations in pediatric patients, have not been well established in many product labels; consult the specific product labeling and a pediatrician.

Elderly (Geriatric) Use

Glymin should be used with caution in elderly patients due to the age-related decline in renal function, which increases the risk of lactic acidosis. Renal function should be assessed more frequently, and dosing should not be titrated to the maximum dose unless renal function is confirmed normal.

Renal Impairment

See Dosage and Administration for eGFR-based dosing recommendations; Glymin is contraindicated at eGFR less than 30 mL/min/1.73 m².

Hepatic Impairment

Avoid use in patients with clinically evident hepatic disease due to increased risk of lactic acidosis.

Glymin is typically used long-term as part of chronic management of type 2 diabetes mellitus, with duration guided by ongoing glycemic control (e.g., HbA1c targets), tolerability, and renal function, as determined by the treating physician. It is not intended for short-course or as-needed use. Periodic reassessment (including renal function and vitamin B12 status) is recommended throughout treatment.

Biguanide; oral antihyperglycemic (antidiabetic) agent.

Metformin Hydrochloride reduces blood glucose primarily by decreasing hepatic glucose production (via inhibition of gluconeogenesis and glycogenolysis), increasing peripheral tissue (skeletal muscle) sensitivity to insulin, and modestly decreasing intestinal absorption of glucose. It works partly through activation of AMP-activated protein kinase (AMPK). Metformin Hydrochloride does not stimulate insulin secretion from pancreatic beta cells and therefore does not typically cause hypoglycemia when used as monotherapy.

Glymin (immediate-release) is approved for use in children 10 years of age and older with type 2 diabetes mellitus, as an adjunct to diet and exercise, either as monotherapy or in combination with insulin. Dosing is weight/age-based and should be titrated gradually starting at 500 mg twice daily with meals up to a maximum of 2000 mg/day in divided doses (see Dosage and Administration). Safety and efficacy of extended-release Glymin in pediatric patients, and of any formulation in children under 10 years, are not well established in many product labels - use only under pediatric endocrinology or specialist supervision.